key: cord-0691462-uo4e1niq authors: Shongwe, M S; Mpe, M J title: Bullous lung disease in association with an isolated giant plexiform neuroma: A case report and brief review of pulmonary involvement in neurofibromatosis type 1 date: 2021-12-31 journal: Afr J Thorac Crit Care Med DOI: 10.7196/ajtccm.2021.v27i4.128 sha: c77d3887be246316a518ba4c21f8e725d594598d doc_id: 691462 cord_uid: uo4e1niq Neurofibromatosis is common. It can be accompanied by abnormalities related to the thorax. These vary in severity and can be life-threatening. We present a case of plexiform neuroma with associated extensive bullous lung disease. Neurofibromatosis type 1 (NF1) affects ~1 in 2 000 -3 000 live births. [1] Approximately half of the cases are sporadic, and the other half are familial with autosomal dominant inheritance. Penetrance is complete but the clinical manifestations and disease severity are variable, even within the same family. [2] Plexiform neuromas are among the most common and debilitating complications of NF1. They occur in about 30% of patients with NF1, and they have been described to occur in isolation. [3, 4] They are benign, diffuse tumours, originating from nerve cell sheaths and can involve multiple fascicles. They are subject to malignant transformation. The first description of pulmonary involvement in patients with NF1 was over half a century ago. [5] Since then, there have been several case series and case reports worldwide. We are aware of only one case report in South Africa that was described >30 years ago, and it is believed that there are likely to be more. [6] Thoracic involvement can be severe and life threatening. [7, 8] Virtually all components of the thorax can be involved. The abnormalities have been clearly demonstrated on high-resolution chest CAT scans, and in some cases, surgical lung biopsy. [9, 10] Neurofibromas can be found in the skin and subcutaneous tissue of the chest wall. [9] Defects in the development of the thoracic skeleton lead to varying degrees of kypho-scoliosis, vertebral abnormalities, and characteristic rib deformities. [11] Neurofibromata arising from the pleuro-parenchymal nerves, as well as endobronchial neurofibromata have been described, although these are rare. [12] An association between NF1 and lung cancer has been proposed following reports of a few scattered cases of NF1 and lung cancer. [13, 14] Additional studies with larger cohorts are necessary to firmly establish NF1 as a risk factor for lung cancer Diffuse parenchymal lung disease occurs in ~10 -20% of individuals. [13] Pathologically, interstitial fibrosis with lymphoplasmocytic inflammation consistent with nonspecific interstitial pneumonitis has been described. [10, 13] The interstitial reticulations predominate at the lung bases. The pathogenesis of the fibrotic process is thought to be secondary to the mesenchymal defect that leads to primary deposition of collagen. [10] Elevated serum levels of nerve growth factor have also been described. This factor is known to directly stimulate fibroblasts differentiation into more pro-fibrogenic myofibroblasts. [15] Other interstitial/parenchymal findings have included micro-nodules, ground-glass opacities, cysts, emphysematous bullae, and honeycombing. [10] The cysts have tended to predominate in the upper lung fields in the central and subpleural locations. Mediastinal lesions in the form of neurofibromata, malignant peripheral nerve tumours and lateral meningocoeles have been observed. [10] Pulmonary arterial hypertension is a rare but serious complication of NF1 and carries a poor prognosis. [8] Its pathogenesis is not clearly understood and likely multifactorial. While it may be secondary to the architectural distortion and hypoxia resulting from the underlying lung disease, pulmonary vasculopathy associated with NF1 has also been postulated. [16] NF1 has a well-known association with systemic vasculopathy, affecting multiple vessels. In addition, neurofibrin, an NF1-encoded protein, is expressed in endothelial and smooth-muscle cells. It regulates cell growth and proliferation, and its deficiency is expected to interfere with the response of these vessels to growth suppressor signals. [16] The general care of adult patients with NF1 is summed up in guideline documents. [17] Targeted treatment of the specific thoracic complication is largely the same as pathologically similar pulmonary problems in the general population. Patient education is important in relation to the use of tobacco products and timely report of respiratory symptoms. Routine radiological screening for the chest manifestations is not recommended by most NF1 guidelines. [17] However, it remains advisable for patients to be offered regular clinic visits so complications can be detected early and appropriate treatment, where available, initiated timeously. Declaration. None. Neurofibromatosis type 1 revisited Pulmonary complications of type 1 neurofibromatosis Isolated plexiform neuroma of arm with unusual presentation -a rare case report Isolated plexiform neuroma mimicking a vascular lesion Diffuse pulmonary involvement in von Recklinghausen's disease: A new syndrome Neurofibromatosis (von Recklinghausen's disease) -an unusual cause of parenchymal lung disease Subclavian artery branch pseudoaneurysm rupture with massive hemothorax in a patient with neurofibromatosis type 1 Pulmonary arterial hypertension: A rare yet fatal complication of neurofibromatosis type 1 Computed tomography (CT) findings in 88 neurofibromatosis 1 (NF1) patients: Prevalence rates and correlations of thoracic findings Neurofibromatosis-associated lung disease: A case series and literature review Imaging of thoracic wall abnormalities Intrathoracic peripheral nerve sheath tumorsa clinicopathological study of 75 cases Neurofibromatosis type 1: Stateof-the-art review with emphasis on pulmonary involvement Coronal chest computed tomography cut showing marked dilatation of pulmonary arteries Lung cancer associated with neurofibromatosis type I Increased serum levels of nerve growth factor in von Recklinghausen's disease Care of adults with neurofibromatosis type 1: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)